Report Overview

The Respiratory diseases drugs market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

With the rise in the outdoor pollution in urban Kenya due to rapid urbanization and high prevalence of the use of wood and charcoal for cooking in Kenyan households, respiratory care is likely to receive particular attention. Based on results of International Study of Asthma and Allergies in Childhood (ISAAC), there was an increase in the prevalence of asthma symptoms in 13-14 years aged children from 17.1% to 18% in Nairobi. In Kenya COPD is estimated to cause approximately the same amount of DALYs as ischemic heart disease, stroke and epilepsy indicating that it is grossly underdiagnosed and treated. According to WHO, about 86.1% of adults are exposed to tobacco smoke in bars and night clubs and 24.8% of youth being exposed at home. Exposure to smoke and chemical pollutants is one of the main causes of developing COPD.



Market Drivers

The market is majorly driven by the rising burden of respiratory diseases. The factors responsible for the development of respiratory diseases include aging, environmental pollution, occupational pollution, use of biofuels, wood and charcoal for cooking and genetics. According to the Global Asthma Report 2018, Asthma in children in Kenya remains a challenging issue. Increase in pollution due to rapid urbanization will drive demand in the respiratory diseases Drugs market. Surge in smokers is expected to stimulate growth in the market.

The increasing incidence of respiratory diseases and presence of strong pipeline drugs in the market are leading to an enormous growth opportunity.

However, Lack of community awareness and underestimating the severity of asthma and other respiratory diseases are restraining the market growth.